贝伐单抗治疗法与低概率的严重不良反应有关。
Bevacizumab treatment was associated with a low rate of serious adverse events.
贝伐单抗是静脉给予每两至三个星期。
Bevacizumab is given intravenously every two to three weeks.
接受更高剂量的贝伐单抗的患者有更大的患蛋白尿的风险。
Patients taking higher dosages of bevacizumab had the greatest risk of developing proteinuria.
接受更高剂量的贝伐单抗的患者有更大的患蛋白尿的风险。
Patients taking higher dosages of bevacizumab had the greatest risk of developing proteinuria .
两项对联合应用贝伐单抗和西妥昔单抗的随机试验结果还须等待。
The results of two randomized trials looking at the combination of bevacizumab and cetuximab are awaited.
用贝伐单抗治疗复发性卵巢上皮癌的患者中，哪种因素可以预测肠道并发症？
Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
结果：共有301例病人被随机分到安慰剂组，306例被随机分到贝伐单抗组。
Results A total of 301 patients were randomly assigned to the placebo group and 306 to the bevacizumab group.
目的观察贝伐单抗与化疗药物联合用于晚期结直肠癌一线治疗的近期疗效和安全性。
OBJECTIVE To evaluate the efficacy and safety of bevacizumab when added to first-line irinotecan-based chemotherapy in patients with metastatic colorectal cancer.
是否使用贝伐单抗、原发肿瘤的位置以及转移病灶的负荷均与干预措施的频率无关。
Neither use of bevacizumab, location of the primary tumor in the rectum, or metastatic disease burden were associated with increased intervention rate.
贝伐单抗，也是没有用的情况下鳞状细胞癌，因为它会导致出血，从这种类型的肺癌。
Bevacizumab is also not used in cases of squamous cell cancer, because it leads to bleeding from this type of lung cancer.
吉西他滨合用贝伐单抗的患者中位生存期为5.7个月，而单用吉西他滨者为6个月。
The median survival for patients taking both Avastin and Gemzar was 5.7 months compared with 6.0 months for patients taking Gemzar alone.
例如，美国应用贝伐单抗治疗直肠结肠癌以及埃罗替尼治疗肺癌是欧洲平均水平的10倍。
For example, the use of bevacizumab for colorectal cancer and erlotinib for lung cancer in the United States was 10 times higher than the European average.
贝伐单抗通过抑制被称为血管内皮生长因子的蛋白，来抑制肿瘤组织的新生血管的生长。
Bevacizumab blocks a protein called vascular endothelial growth factor, thus inhibiting the production of new blood vessels around tumors.
该研究中，302名患者接受吉西他滨合用贝伐单抗，300名患者接受吉西他滨和安慰剂。
The study researchers assigned 302 patients to receive Avastin and Gemzar and assigned an additional 300 patients to receive Gemzar plus placebo.
由美国食品与药品管理局批准治疗转移克隆癌的贝伐单抗，是血管内皮生长因子的单克隆抗体。
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, is approved by the US Food and Drug Administration for metastatic colon cancer.
在术前，患者每两周一次静脉接受贝伐单抗，持续四周；同时，每天口服埃罗替尼，持续八周。
The patients received bevacizumab intravenously once every two weeks for four weeks and took erlotinib orally every day for eight weeks before they had surgery.
第一年，进行贝伐单抗注射的32%的患者的可认字母增加了15个，而标准治疗方案组的患者增加了3%。
At one year, 32% of patients in the bevacizumab group gained 15 or more letters from baseline visual acuity compared with 3% in the standard care group.
贝伐单抗阻断血管内皮生长因子(VEGF)受体活性，是肿瘤血管生成，增殖和转移的重要因子。
Bevacizumab blocks the action of the vascular endothelial growth factor (VEGF) receptor, a key factor in tumor angiogenesis, growth, and metastasis.
在2006年6月，数据监测和安全委员会发现加用贝伐单抗并不能使患者受益，于是停止了该研究。
The study was halted prematurely in June 2006 when the Data Monitoring and Safety Board determined that there did not appear to be any benefit to patients in continuing to take bevacizumab.
在第三个治疗周期后，贝伐单抗与显著增多的毒性事件有关系，特别是发热引起的粒细胞减少和肺出血。
After the third treatment cycle, bevacizumab was associated with significantly more toxic events, particularly febrile neutropenia and pulmonary hemorrhage.
欧美权威机构接受PFS作为观察终点，而非总生存期（OS），肾细胞癌作为贝伐单抗的适应症范围。
PFS, rather than overall survival (OS), was accepted by regulatory authorities in the United States and Europe as the endpoint for approval of bevacizumab for the renal cell carcinoma indication.
采用化学治疗药物(贝伐单抗，是中和血管内皮生长因子的人源化抗体)治疗可导致蛋白尿和肾功能损害。
Treatment with the chemotherapeutic agent bevacizumab, a humanized mab that neutralizes vascular endothelial growth factor, can lead to proteinuria and renal damage.
研究结果建议对于患有肾癌的使用贝伐单抗的患者和使用大剂量贝伐单抗的患者对肾脏进行检测特备重要。
These results indicate that it is particularly important to monitor the effects of bevacizumab in patients who have kidney cancer or who are receiving high doses of the drug.
排除鳞状细胞肺癌的患者和那些治疗前有咯血的患者后，贝伐单抗治疗导致的致命率就会下降到1.9%。
By excluding patients with squamous-cell lung cancer and those with hemoptysis prior to treatment, the rate was brought down to 1.9%.
尽管导致患者死亡的原因主要是肺癌，但是贝伐单抗组的14名患者以及对照组的2名患者却死于药物毒性。
Causes of death were predominantly due to lung cancer, but 14 patients in the bevacizumab group and 2 in the control group died as a result of drug toxicity.
例外的是，这些药物也有临床明显的药物副作用——贝伐单抗可致高血压，吉非替尼和厄洛替尼可有皮肤毒性。
Fortuitously, these drugs also have clinically obvious pharmacodynamic end points-hypertension for bevacizumab and skin toxicity for erlotinib and gefitinib.
差别最为悬殊的是新型抗结肠直肠癌及肺癌药物的应用，这些药物包括贝伐单抗、西妥昔单抗、埃罗替尼及培美曲塞。
The largest disparities were in the use of the new colorectal and lung cancer drugs: bevacizumab, cetuximab, erlotinib and pemetrexed, the study found.
目的：评估在局部进展期直肠癌患者中联合贝伐单抗和标准放化疗的新辅助治疗有效性和安全性，并探索标志物反应。
Purpose To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response.
我们对已发表的随机、对照试验进行一项系统性回顾和荟萃分析，以评估应用贝伐单抗治疗引起重症蛋白尿的整体风险。
We performed a systematic review and meta-analysis of published randomized, controlled trials to assess the overall risk for severe proteinuria with bevacizumab.
我们对已发表的随机、对照试验进行一项系统性回顾和荟萃分析，以评估应用贝伐单抗治疗引起重症蛋白尿的整体风险。
We performed a systematic review and meta-analysis of published randomized, controlled trials to assess the overall risk for severe proteinuria with bevacizumab.
应用推荐